In contrast, a phase III open-label randomized controlled trial showed that Enhertu (Trastuzumab deruxtecan/T-DXd) was effective in patients with ERBB2 under/over-expressed breast cancer and gastric cancer [31, 32]. The gene discussed is ERBB2; the disease is gastric cancer.